The CD4+ T-lymphocyte count is an important predictor for the prognosis of cryptococcosis

Y. Ding1 · P. Li1 · Q. He2 · H. Wei3 · T. Wu1 · D. Xia1 · M. Tan1 · Y. Shi1 · X. Su1

Abstract There is great heterogeneity of immunity among patients with cryptococcosis, and severe immunodeficiency can lead to negative clinical outcomes. Underlying disease is a poor surrogate for immune status and inferior in predicting an individual’s prognosis. This study was intended to determine whether T-lymphocyte subgroups would be more suitable indicators regarding the severity of infection and clinical outcomes of such patients. We retrieved clinical data on 101 patients with cryptococcosis and compared the validity of multiple parameters (underlying disease and T-lymphocyte subgroups) in predicting the severity of infection and clinical outcome in these patients. For patients with CD4+ T-lymphocyte counts lower than 400/μL, the odds ratio of disseminated cryptococcosis was 23.3 (P = 0.005). There was a moderate negative correlation between CD4+ T-cell count and Apache II score (−0.609, P < 0.001). Mortality among patients with low levels of CD4+ T lymphocytes was significantly higher than among those with normal levels (23.8% vs 5.3%, P = 0.016). However, the difference was not significant if the patients were grouped by underlying disease (P = 0.067). The CD4+ T-lymphocyte count in peripheral blood is a simple and more accurate biomarker for predicting severity of infection and clinical outcome in patients with cryptococcosis.

Introduction

Cryptococcosis is a potentially life-threatening systemic mycosis [1]. Inhalation of Cryptococcus spores is the main route of infection; such spores may remain isolated in the lungs or spread to other organs, depending on the host’s immune status [2]. The central nervous system (CNS) is considered to be the most vulnerable organ involved in this process. Disseminated disease, especially CNS involvement, often points to a need for timely, aggressive treatment [3] and a much higher mortality without it [4]. Thus, the risk factors for dissemination (i.e., the host’s immune status or underlying diseases) are always the top concerns of clinicians seeking to manage this infection.

With their significantly heterogeneous levels of immunity, those susceptible to infection with Cryptococcus include patients with human immunodeficiency virus (HIV)/adult immunodeficiency syndrome (AIDS), organ transplant recipients [5], and patients with sarcoidosis [6], liver failure [7], leukemia [8], or diabetes mellitus [9] as well as those receiving aggressive drug therapy [10]. Cryptococcosis may, in fact, arise even in patients with no underlying disease [11, 12]. In other words, these patients may have various degrees of immune deficiency and risk for dissemination. Up to now, clinical guidelines have recommended that clinicians evaluate their patients’ underlying diseases and take the findings as one of the main classification criteria for planning a therapeutic regimen. But we found this approach inadequate. In short, it is imperative to find other parameters for evaluating patients’ immune status and predicting disease severity and clinical outcome.
Many studies suggest that cell-mediated immunity, especially in terms of T lymphocytes, plays an important role in countering cryptococcal infection [13–15]. For example, AIDS patients have been characterized by CD4+ T-cell depletion and inversion of the CD4+/CD8+ ratio [16]. One recent study from Germany suggested that routine screening for cryptococcosis by testing with cryptococcal antigen (CRAG) is highly recommended for AIDS patients with CD4+ T-cell counts ≤ 200/µL [17]. Another example involves the use of rabbit anti-thymocyte globulin and alemtuzumab, which have been given to organ transplant patients to counteract acute rejection; however, this treatment can induce a substantial decline in the number of CD4+ T cells and thus increase the risk of cryptococcal infection [18]. Idiopathic CD4+ T lymphocytopenia has also been reported to be an important predisposing factor for cryptococcosis [19, 20]. By the recruitment of granulocytes and macrophages in the lungs and the production of IL-12, TNF-α, and IFN-γ, CD4+ T cells have been shown to protect mice against cryptococcal infection [15]. All these examples show that T lymphocyte subgroups play an important role in the pathogenesis of cryptococcosis.

Clinicians need a simple, straightforward indicator to determine an individual’s immune status and thus to predict the risk of disseminated cryptococcal disease and its potential severity, also keeping in mind other possible underlying diseases. T-lymphocyte subgroups constitute quantitative parameters; their numbers can readily be determined in routine clinical practice. With this in mind, we launched a retrospective study to compare the predictive role of underlying diseases and T-lymphocyte subgroups for patients with cryptococcosis and to find out which parameter would have the greatest predictive power.

Methods and materials

We retrieved the clinical data of adult cryptococcosis patients in Jingling Hospital, and the Second Hospital of Nanjing, Nanjing, China. The diagnosis of cryptococcosis was confirmed either by histopathological examination of tissue samples (obtained by percutaneous lung biopsy, surgical resection, bronchoscope biopsy) or by positive staining/culture results from cerebrospinal fluid and/or blood. Clinical diagnoses were made on the basis of typical clinical manifestations and the cryptococcal antigen test. We ruled out those suspected cases that did not fulfill our diagnostic criteria as well as cases that did not include data on the peripheral blood T-lymphocyte subgroups at the time of diagnosis.

According to the classification criteria of the clinical practice guidelines for the management of cryptococcal disease published by the Infectious Disease Society of America in 2010, patients with cryptococcosis fall into several groups: the AIDS group, organ transplantation recipient (OTR) group, and NHNT (non-HIV-infected and non-transplant host) group. Patients with HIV infection and those who have received solid organ transplants were allocated to the AIDS and OTR groups, respectively. Since the heterogeneity of the NHNT group is quite large, this group was divided again [21] into the NHNT-1 group (where the patient suffered from one or more diseases that can cause mild or moderate immune deficiency and increase the risk of infection, such as autoimmune disease, diabetes mellitus, hematological disease, and so on) and the NHNT-2 group (comprising patients with no detectable immunological defects or underlying diseases).

Flow cytometry performed by professional technicians was used to analyze T-lymphocyte subgroups among our patients at admission. In addition, the findings on chest CT were described by two radiologists at Jinling Hospital.

Apache II scores and acute physical and chronic health evaluations were widely applied to assess the severity of disease [12, 22]. Integral scores ranged from 0 to 71, a higher score indicating a more severe condition and poorer prognosis. This score was determined according to the patient’s condition prior to antifungal therapy. Survival at the conclusion of our study (follow-up of at least 3 months for each patient [4]) constituted the clinical outcome. All data were acquired from medical records or telephone follow-up.

Statistical analysis

Data were described as means (standard deviation) and percentages. One-way analysis of variance, t-tests, and chi-square tests were used in comparing the baseline characteristics. Because of the heterogeneity of our data, T-lymphocyte subgroups were expressed in terms of the median; the Kruskal-Wallis H test was applied in comparing the four groups; subsequently the Nemenyi test was used to make paired comparisons. The cutoff value of parameters was determined by receiver operating characteristic (ROC) curves and Youden’s index. The association was assessed by Spearman’s correlation analysis. The chi-square test was used in comparing groups. Significance was defined as P < 0.05 with two-sided analysis. We analyzed all data with SPSS software, version 17.0.

Results

Between January 2009 and July 2015, a total of 106 proven cases of cryptococcosis were collected, including an AIDS group (n = 30), an OTR group (n = 15), a NHNT-1 (n = 32) group, and a NHNT-2 (n = 29) group. The AIDS patients were characterized by a substantial decrease in the number of CD4+ T cells, and OTR patients had to be treated with immunosuppressants, so their T-lymphocyte counts were also low. All T-lymphocyte counts were routinely evaluated in these patients.
Two NHNT-1 cases and three NHNT-2 cases had not been studied for T-lymphocyte subgroups. In sum, 101 cases met all our criteria and were therefore included in this study. There were 73 male and 28 female patients from 16 to 78 (41.4 ± 13.6) years of age. Of the total, 26 patients had no comorbidity (NHNT-2 group). The other 75 patients were assigned to the AIDS group (n = 30), OTR group (n = 15), or NHNT-1 group (n = 30). The demographic data for each group are listed in Table 1.

All 15 patients in the OTR group were kidney transplant recipients. The NHNT-1 patients suffered from various underlying diseases, including lupus nephritis, nephritic syndrome, lymphoma, and so on. NHNT-2 patients had no detectable diseases that could compromise their immune systems. Except for the underlying diseases, the baseline characteristics of each group were comparable (P > 0.05) (Table 1).

The definition of disseminated cryptococcosis includes the involvement of CNS involvement, at least two noncontiguous sites [17] or cryptococeemia [17]. Local cryptococcosis [17] is defined as pulmonary cryptococcosis with or without pleural effusion or as focal lymphadenopathy. Our study showed that the proportions of disseminated disease in the AIDS, OTR, NHNT-1, and NHNT-2 groups were 86.7%, 80%, 50%, and 11.5%, respectively, and the difference between groups reached statistical significance (P < 0.001) (Table 1). It is noteworthy that the dissemination rate in the NHNT-1 group was much higher than we had expected. One reason may be that most of these patients had been receiving aggressive treatment with immunosuppressants before the onset of cryptococcosis.

### T-lymphocyte subgroups

The median of CD4+ T cell counts in the AIDS group was much lower than that in the OTR, NHNT-1, or NHNT-2 groups, with statistical significance (median, 18 vs 270, 214, and 663; P < .001). The median of CD4+ T-cell counts in the NHNT-2 group was greater than that in the OTR group (median, 663 vs 270; P < .05) and NHNT-1 group (median 663 vs 214; P < .005) (Fig. 1a).

CD8+ T-cell counts in the OTR and NHNT-1 groups were lower than those in the AIDS and NHNT-2 groups (median, 215, 247 vs 432.5, 477.5; P = 0.004) (Fig. 1b). The median of CD3+ T-cell counts in the NHNT-2 group was much higher than that in the AIDS, OTR, and NHNT-1 groups, with statistical significance (1213.5 vs 471.5, 528, 461.5; P < 0.001) (Fig. 1c).

CD4+/CD8+ ratio in the AIDS group was lower than OTR, NHNT-1 and NHNT-2 groups with statistical significance (median, 0.04 vs 1.39, 0.72, 1.52; P < 0.001). The difference in CD4+/CD8+ ratio between the NHNT-1 group and the NHNT-2 group reached statistical significance (median, 0.72 vs 1.52; P < 0.05) (Fig. 1d).

### Table 1 Demographic data on 101 patients with cryptococcosis, 2009–2015

| Characteristic          | AIDS, n = 30 | OTR, n = 15 | NHNT-1, n = 30 | NHNT-2, n = 26 | P value |
|-------------------------|--------------|-------------|----------------|----------------|---------|
| Male                    | 26 (86.7%)   | 11 (73.3%)  | 17 (56.7%)     | 19 (73.1%)     | 0.074   |
| Age (years)             | 37.8 ± 11.5  | 42.8 ± 12.9 | 42.3 ± 17.4    | 43.9 ± 10.4    | 0.219   |
| Underlying disease      |              |             |                |                |         |
| SOT (kidney)            | None         | 15          | None           | None           |         |
| Renal disease           | None         | 15          | 12 (40%)       | None           |         |
| AID                     | None         | None        | 11 (36.7%)     | None           |         |
| Hemopathy               | None         | None        | 5 (16.7%)      | None           |         |
| Diabetes mellitus       | None         | 3 (20%)     | 6 (20%)        | None           |         |
| ILC                     | None         | None        | 4 (13.3%)      | None           |         |
| Liver dysfunction       | None         | None        | 1 (3.3%)       | None           |         |
| Site of infection       |              |             |                |                |         |
| Disseminated            | 26 (86.7%)   | 12 (80%)    | 15 (50%)       | 3 (11.5%)      | <0.001  |
| Local                   | 4 (13.3%)    | 3 (20%)     | 15 (50%)       | 23 (88.5%)     |         |

AID autoimmune disease, AIDS acquired immunodeficiency syndrome, ICL idiopathic CD4+ lymphopenia, NHNT non-HIV-infected and non-transplant host, OTR organ transplantation recipient, SOT solid organ transplant.

Renal disease in the NHNT-1 group included lupus nephritis (n = 8), nephritic syndrome (n = 2), podocytopathy (n = 1) and allergic tubule-interstitial nephritis (n = 1).

Autoimmune disease included SLE (n = 8), pemphigoid (n = 1) and rheumatoid arthritis (n = 2).

Hemopathy included malignant lymphoma (n = 2), myelodysplastic syndromes (n = 2) and allergic purpura (n = 1).

The data was described in percentage or mean (standard deviation). One-way analysis of variance and chi-square test were used in comparison between groups.
The predictive value of these parameters in assessing the risk of disseminated cryptococcosis

First, our study sought to determine whether the parameters of cell-mediated immunity are more accurate than the underlying disease burden in predicting the incidence of dissemination. Second, we sought to discover which of the T-lymphocyte subgroups would be the most sensitive predictor. We applied the ROC curves and Youden’s index to determine the cutoff value of T-lymphocyte subgroups. Then we found the cutoff value of CD4+ T cell counts of 400/μL for predicting dissemination; the sensitivity and specificity were 80% and 98.2%. The area under concentration-time curve (AUC) was 0.903 and the 95% confidence interval ranged from 0.835 to 0.970 (These data are shown in ESM_Figure2A). Similarly, supposing 617/μL to be the cutoff value of CD3+ T-cell counts, the sensitivity and specificity to predict the dissemination were 86.7% and 82.1%, respectively. The AUC was 0.890 and the 95% confidence interval ranged from 0.823 to 0.957 (the data are shown in ESM_Figure2B). Because of the poor result of AUC in CD8+ T cells (0.732) and the CD4+/CD8+ ratio (0.777), the normal lower limit (242/μL, 0.90) was chosen as the cutoff value.

Then we reclassified the patients according to the following criteria: (1) Underlying disease: the patients with AIDS/OTR (n = 45) were classified in the group with severe underlying disease (group A) and the remainders (n = 56) in the group without severe underlying disease (group B). (2) CD4+/CD8+ ratio: the patients with a CD4+/CD8+ ratio below the normal lower limit (n = 59) were classified in group C, and the others (n = 42) in group D. (3) CD8+ T-lymphocyte count: the patients with CD8+ T-lymphocyte counts lower than 242/μL (n = 28) were classified in group E and the others (n = 73) in group F. (4) CD3+ T-lymphocyte count: the patients with CD3+ T-lymphocyte counts below 617/μL (n = 52) were classified in group G and the remaining patients (n = 49) in group H. (5) CD4+ T-lymphocyte count: the patients with CD4+ T-lymphocyte counts below 400/μL (n = 63) made up group I, while the normal (n = 38) patients were classified in group J. The differences between groups in terms of most baseline characteristics according to different classification criteria were comparable (P > 0.05) (these data are shown in ESM_Table).

On further study, we evaluated the predictive role of underlying diseases and T-cell subgroups regarding disease severity and prognosis according to the various classifications. First, we screened the risk factors that could best predict the general distribution of lesions by single-factor logistic regression analysis. Our study showed that both underlying disease and the parameter of T-lymphocyte subgroups had an effective role in predicting the risk of disseminated cryptococcosis. However, we did not find a close link between male gender/age and incidence of dissemination (Table 2). In consideration of interactions, multivariable logistic regression analysis was applied, and our data suggested that the CD4+ T-lymphocyte count was the most sensitive predictor; the odds ratio was 23.3 (95% CI: 2.6–209.7; P = .005), while the other parameter did not reach statistical significance (P > 0.05) (Table 3). With regard to influence on the distribution of pulmonary lesions, the proportion of unilateral lung lesion in groups A, C, E, G, and I were 66.7%, 61.5%, 42.9%, 53.6%, and 55.6% vs 44.1%, 58.6%, 64.8%, 65%, and 65.6% in groups B, D, F, group H, and J, respectively. There was no statistical significance in these comparisons (P > 0.05) (Table 4).
The role in assessing the disease severity and mortality

A moderate negative correlation was found between the CD4⁺ T-cell count and Apache II score. The correlation coefficient was $-0.609$ ($P < 0.001$), which was higher than that of CD3⁺ T-cell count ($-0.572$), underlying disease ($-0.471$), CD8⁺ T-cell count ($-0.384$) and CD4⁺/CD8⁺ ratio, respectively ($-0.276$) ($P < 0.05$) (Table 5). Our study further evaluated the predictive role of underlying disease and T-lymphocyte subgroups with regard to mortality. The mortality of the patients with decreased CD4⁺ T lymphocytes was 23.8%, which was higher than that (5.3%) of the patients with normal CD4⁺ T lymphocyte ($P = 0.016$). The mortality of cryptococcosis patients with severe underlying diseases was slightly higher than that in the patients with relatively mild diseases, but the difference did not reach statistical significance (24.4% vs 10.7%; $P = 0.067$). There was also no statistical significance among the other parameters ($P > 0.05$) (Table 6).

| Characteristic                  | Disseminated, n = 56 | Localized, n = 45 | Odds ratio (95% CI) | P value |
|---------------------------------|----------------------|-------------------|---------------------|---------|
| Male (n = 73)                   | 38 (67.9%)           | 35 (77.8%)        | 0.6(0.2–1.5)        | 0.270   |
| Age < 50 (n = 78)               | 47                   | 31                | 2.4(0.9–6.1)        | 0.077   |
| Severe underlying disease (n = 45) | 38 (68.9%)           | 7                 | 11.5(4.3–30.6)      | <0.001  |
| Decreased CD4⁺/CD8⁺ ratio (n = 59) | 43                  | 16                | 6.0(2.5–14.3)       | <0.001  |
| Decreased CD8⁺ T-cell count (n = 28) | 25                  | 3                 | 11.3(3.1–40.8)      | <0.001  |
| Decreased CD3⁺ T-cell count (n = 52) | 46                  | 6                 | 29.9(10.0–89.7)     | <0.001  |
| Decreased CD4⁺ T-cell count (n = 63) | 54                  | 9                 | 108.0(22.0–529.2)   | <0.001  |

Single-factor logistic regression analysis was used to screen the predictors in assessing the risk of dissemination cryptococcosis.

Discussion

As far as we know, data on T-lymphocyte subgroups in patients with cryptococcosis have been derived mainly from AIDS patients, whereas studies related to non-AIDS patients have been rare. Therefore our study reviewed the data on T-lymphocyte subgroups in patients with cryptococcosis from eastern China and considered the role of cell immunity in assessing disease severity and prognosis.

We observed consistent results in AIDS patients, whose CD4⁺ T lymphocytes were lower than 50/μL in 83.3% cases and lower than 200/μL in 96.7% cases. Previous research also found CD4⁺ T-lymphocyte counts lower than 50/μL in 97% of AIDS patients suffering from crypto-
coccosis [23]. Inversion of the CD4⁺/CD8⁺ ratio was found in all the AIDS patients in our study [16]. Furthermore, a clear-cut result was derived from the NHNT-2 patients in that most of their CD4⁺ and CD8⁺ T-cell counts were normal, but the CD4⁺/CD8⁺ ratio was decreased in some patients.
Other than AIDS and NHNT-2 patients, a heterogeneous result was obtained in OTR and NHNT-1 patients. The number of CD4+ T-lymphocytes decreased in 80% and CD8+ T cells decreased in 53.3% of the OTR patients, but their CD4+/CD8+ ratios generally remained normal. Some patients in the NHNT-1 group resembled those in the AIDS or OTR groups and others were similar to patients in the NHNT-2 group. Overall we found that cryptococcosis patients exhibit an obvious heterogeneity of immune status.

The levels of CD8+ T cells were normal or increased in the AIDS patients, whereas they were sharply decreased in the OTR patients and those receiving large doses of immunosuppressants. It should be emphasized that a decrease in the CD8+ T-cell count can lead to a normal CD4+/CD8+ ratio in patients with low numbers of CD4+ lymphocytes [24]. In short, our

### Table 4

| Characteristic                        | Unilateral lung, n = 41 | Bilateral lung, n = 27 | P value |
|---------------------------------------|-------------------------|------------------------|---------|
| Underlying disease                    |                         |                        |         |
| Group A (n = 24)                      | 16(66.7%)               | 8(33.3%)               | 0.428   |
| Group B (n = 44)                      | 25(44.1%)               | 19(55.9%)              |         |
| CD4+/CD8+ ratio                      |                         |                        |         |
| Group C (n = 39)                      | 24(61.5%)               | 15(38.5%)              | 0.808   |
| Group D (n = 29)                      | 17(58.6%)               | 12(41.4%)              |         |
| CD8+ T cell count                     |                         |                        |         |
| Group E (n = 14)                      | 6(42.9%)                | 8(57.1%)               | 0.135   |
| Group F (n = 54)                      | 35(64.8%)               | 19(35.2%)              |         |
| CD3+ T cell count                     |                         |                        |         |
| Group G (n = 28)                      | 15(53.6%)               | 13(46.4%)              | 0.343   |
| Group H (n = 40)                      | 26(65%)                 | 14(35%)                |         |
| CD4+ T cell count                     |                         |                        |         |
| Group I (n = 36)                      | 20(55.6%)               | 16(44.4%)              | 0.397   |
| Group J (n = 32)                      | 21(65.6%)               | 11(34.4%)              |         |

Chi-square test was used to compare the difference in proportion of bilateral lung lesion between two groups.

### Table 5

| Characteristic                        | APACHE II score | Correlation coefficient | P value |
|---------------------------------------|-----------------|-------------------------|---------|
| Underlying disease                    |                 |                         |         |
| Group A (n = 45)                      | 6               | 16                      | 23      | −0.471 | <0.001 |
| Group B (n = 56)                      | 38              | 5                       | 13      |         |       |
| CD4+/CD8+ ratio                       |                 |                         |         |
| Group C (n = 59)                      | 16              | 20                      | 23      | −0.276 | 0.006  |
| Group D (n = 42)                      | 28              | 1                       | 13      |         |       |
| CD8+ T cell count                     |                 |                         |         |
| Group E (n = 28)                      | 3               | 9                       | 16      | −0.384 | <0.001 |
| Group F (n = 73)                      | 41              | 12                      | 20      |         |       |
| CD3+ T cell count                     |                 |                         |         |
| Group G (n = 52)                      | 6               | 19                      | 27      | −0.572 | <0.001 |
| Group H (n = 49)                      | 38              | 2                       | 9       |         |       |
| CD4+ T cell count                     |                 |                         |         |
| Group I (n = 63)                      | 11              | 20                      | 32      | −0.609 | <0.001 |
| Group J (n = 38)                      | 33              | 1                       | 4       |         |       |

The Spearman correlation analysis was used in comparison.

### Table 6

| Characteristic                        | Death*, n = 17 | Survival, n = 84 | P value |
|---------------------------------------|---------------|-----------------|---------|
| Underlying disease                    |               |                 |         |
| Group A (n = 45)                      | 11(24.4%)     | 34(75.6%)       | 0.067   |
| Group B (n = 56)                      | 6(10.7%)      | 50(89.3%)       |         |
| CD4+/CD8+ ratio                       |               |                 |         |
| Group C (n = 59)                      | 12(20.3%)     | 47(79.7%)       | 0.264   |
| Group D (n = 42)                      | 5(11.9%)      | 37(88.1%)       |         |
| CD8+ T-cell count                     |               |                 |         |
| Group E (n = 28)                      | 6(21.4%)      | 22(78.6%)       | 0.640   |
| Group F (n = 73)                      | 11(15.1%)     | 62(84.9%)       |         |
| CD3+ T-cell count                     |               |                 |         |
| Group G (n = 52)                      | 10(19.2%)     | 42(80.8%)       | 0.507   |
| Group H (n = 49)                      | 7(14.3%)      | 42(85.7%)       |         |
| CD4+ T-cell count                     |               |                 |         |
| Group I (n = 63)                      | 15(23.8%)     | 48(76.2%)       | 0.016   |
| Group J (n = 38)                      | 2(5.3%)       | 36(94.7%)       |         |

Chi-square test was used to compare the difference in mortality of cryptococcosis between two groups.

*a Attributed death
study suggests that the value of CD4+/CD8+ ratios, CD8+ T-cell counts, or CD3+ T-cell counts is relatively limited in determining the immune status of patients with cryptococcosis. In a word, the CD4+ T-cell count was felt to be the most valuable parameter in evaluating the cell immunity of the patients in our study.

Disseminated cryptococcosis was tightly linked with the immune status of cryptococcosis patients. Granuloma was among the most common pathological result of pulmonary lesions in cryptococcosis patients; this was mainly induced by CD4+ T-cell immunity [25]. Integrated granuloma may prevent the dissemination of cryptococcal disease. Recent studies show that Th1/Th17 lymphocytes, which are CD4+ T-cell subgroups, may prevent dissemination [26]. The CD4+ T-cell count was sharply decreased (median, 82/μL; range 7–292/μL) in 53 patients with idiopathic CD4+ T lymphocytopenia and cryptococcosis [19]. There was CNS involvement in 75.4% of these patients [19]. CD4+ T-cell counts were also decreased in eight patients with systemic lupus erythematosus who also suffered from cryptococcal meningitis (mean ± SD, 113.2 ± 59.2/μL) [27]. One AIDS study revealed that CD4+ T-cell counts in patients with local cryptococcosis were higher than in those with disseminated cryptococcosis [28]. Our study confirmed that as opposed to underlying disease, the CD4+ T-cell count is a more effective predictor of disseminated cryptococcosis.

Recent studies have reported that the proportions of patchy shadow, consolidation, and cavities in immunocompromised patients were higher than in immunocompetent patients [21, 29, 30]; therefore, we speculated that imaging of the chest in our immunocompromised patients might be more severe than it was in those who were immunocompetent. However, we found that neither underlying disease nor T-lymphocyte subgroups were good predictors for the distribution of lung lesions. Since inhaled cryptococcal spores are the main source of infection, we assumed that their presence might be more important as an indicator of lung lesions.

Joseph et al. discovered that the Cryptococcus-specific CD4+ memory T-cell response to Cryptococcus is closely correlated with clinical severity and outcome in AIDS patients with cryptococcal meningitis [31]. Our study suggests that the total CD4+ T-cell count is also effective in assessing disease severity and mortality among patients either with or without HIV infection.

Inevitably, our study has some limitations. First, it is a retrospective study. Second, our study retrieved data from of T-lymphocyte subgroups at only one time point and before antifungal therapy. Dynamic changes in T-lymphocyte subgroups during the follow-up period were not clear. In a further study, therefore, a prospective design and dynamic follow-up of T-lymphocyte subgroups will be needed.

In conclusion, the CD4+ T-cell count is an effective indicator of a patient’s immune status and provides a more accurate estimate of disease severity and prognosis in cases of cryptococcal infection. In other words, a count of CD4+ T cells in the peripheral blood of each patient with cryptococcosis should be done routinely. For those with low CD4+ T-cell counts, testing for possible dissemination should proceed as promptly as possible.

Acknowledgements I also owe much to my friends and classmates for their valuable suggestions and critiques, which were helpful and important in bringing this project to completion. I thank Accdon for its linguistic assistance during the preparation of this manuscript.

Compliance with ethical standards

Funding This work was supported by grants from the National Natural Science Foundation of China (No. 81330035), Medical and Health Research Foundation of Nanjing Military Command (No. 12MA082) and National Key Technology Support Program from Ministry of Science and Technology (2015BAI12B11).

Conflicts of interest No conflicts for all authors.

Ethical approval For this type of study formal consent is not required.

Informed consent Informed consent was obtained from all individual participants.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Gullo FP, Rossi SA, Sardi Jde C, Teodoro VL, Mendes-Giannini MJ, Fusco-Almeida AM (2013) Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis 32(11):1377–1391
2. Kishi K, Homma S, Kurosaki A, Kohno T, Mooti N, Yoshimura K (2006) Clinical features and high-resolution CT findings of pulmonary cryptococcosis in non-AIDS patients. Respir Med 100(5): 807–812
3. Perfect JR, Dismukes WE, Dromer F et al (2010) Clinical practice guidelines for the management of cryptococcal disease, update by the infectious diseases society of America. Clin Infect Dis 50(3): 291–322
4. Brizendine KD, Baddley JW, Pappas PG (2013) Predictors of mortality and differences in clinical features among patients with cryptococcosis according to immune status. PLoS One 8(3):e60431
5. Singh N, Alexander BD, Lortholary O et al (2007) Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 195(5):756–764
6. Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A, Bahn YS (2014) Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med 4(7):a019760
7. Bratton EW, El Husseini N, Chastain CA et al (2012) Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One 7(8):e43582

8. Barragan NC, Sorvillo F, Kuo T (2014) Cryptococcosis-related deaths and associated medical conditions in the United States; 2000–2010. Mycoses 57(12):741–746

9. Kakeya H, Izumikawa K, Yamada K et al (2014) Three cases of concurrent infection with Mycobacterium tuberculosis and Cryptococcus neoformans. Intern Med 53(15):1685–1692

10. Zhu LP, Wu JQ, Xu B, Ou XT, Zhang QQ, Weng XH (2010) Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997–2007. Med Mycol 48(4):570–579

11. Ye F, Xie JX, Zeng QS, Chen GQ, Zhong SQ, Zhong NS (2012) Retrospective analysis of 76 immunocompetent patients with primary pulmonary cryptococcosis. Lung 190(3):339–346

12. Nguyen MH, Husain S, Clancy CJ et al (2010) Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect 61(5):419–426

13. Wozniak KL, Young ML, Wormald FL Jr (2011) Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol: CVI 18(5):717–723

14. Voelz K, May RC (2010) Cryptococcal interactions with the host immune system. Eukaryot Cell 9(6):835–846

15. Rohatgi S, Pirofski LA (2015) Host immunity to Cryptococcus neoformans. Future Microbiol 10(4):565–581

16. Tinago W, Coghlan E, Macken A et al (2014) Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+ T-cell ratio: effect of naive and memory T-cell subsets. PLoS One 9(5):e97011

17. Katchanov J, Jeffrey L, Tominski D, Wostmann K, Slevogt H, Arasteh K, Stocker H (2015) Cryptococcosis in HIV-infected hospitalized patients in Germany: Evidence for routine antigen testing. J Infect 71(1):110–116

18. Silveira FP, Husain S, Kwak EJ et al (2007) Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis 9(1):22–27

19. Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE (2007) Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine 86(2):78–92

20. Tsalik EL, Jaggers LB (2010) Life-threatening asymptomatic incidentaloma: a case report of idiopathic CD4 lymphocytopenia and opportunistic infections. Am J Med Sci 340(2):158–159

21. Yanagawa N, Sakai F, Takeyama T, Ishikawa S, Takaki Y, Hishima T, Kamata N (2013) Pulmonary cryptococcosis in rheumatoid arthritis (RA) patients: comparison of imaging characteristics among RA, acquired immunodeficiency syndrome, and immunocompetent patients. Eur J Radiol 82(11):2035–2042

22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13(10):818–829

23. Marakutina T, Huprikar S, Azie N, Quan SP, Meier-Kriesche HU, Horn DL (2014) Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study. HIV/AIDS 6:39–47

24. Suarez-Rivera M, Abadeer RA, Kott MM, Braun MC (2008) Cryptococcosis associated with crescentic glomerulonephritis. Pediatr Nephrol 23(5):827–830

25. Miyazaki E, Tsuda T, Onizuka O (1991) Immunohistochemical analysis of granulomatous lung lesion in primary pulmonary cryptococcosis. Nihon KyobuShikkanGakkaizasshi 29(4):444–451

26. Qiu Y, Davis MJ, Dayrit JK et al (2012) Immune modulation mediated by cryptococcal laccase promotes pulmonary growth and brain dissemination of virulent Cryptococcus neoformans in mice. PLoS One 7(10):e47853

27. Gonzalez-Duarte A, Saniger-Alba Mdel M, Higuera-Calleja J (2015) Cryptococcal meningitis in HIV-negative patients with systemic connective tissue diseases. Neurol Res 37(4):283–287

28. Sabiti W, May RC (2012) Mechanisms of infection by the human fungal pathogen Cryptococcus neoformans. Future Microbiol 7(11):1297–1313

29. Chang WC, Tsao C, Hsu HH, Lee SC, Huang KL, Tung HJ, Chen CY (2006) Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest 129(2):333–340

30. Jarvis JN, Casazza JP, Stone HH et al (2013) The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J Infect Dis 207(12):1817–1828